News Roundup: Routine Pediatric Vaccinations Lag Amid Pandemic, FDA Approves Steroid-Free Antihistamine Allergy Nasal Spray
Here’s a roundup of the latest news coverage from Drug Topics®.
Don’t waste time digging through articles to find the most up-to-date and important news. Drug Topics® has you covered with our weekly news roundup of the latest pharmacy-related news you should know before the weekend begins.
Here’s a roundup of the latest news coverage from Drug Topics®.
Blood-Brain Barrier Crossing Antihypertensives Linked to Less Memory Decline
Blood-brain barrier crossing medicines have shown memory benefits in elderly patients, according to a new analysis.
FDA OKs OTC Use of Steroid-Free Antihistamine Allergy Nasal Spray
The FDA has approved OTC azelastine HCl .15% (Astepro Allergy; Bayer).
Routine Pediatric Vaccinations Continue to Lag Amid COVID-19 Pandemic
There was a marked decline in child and adolescent routine vaccine administration during the COVID-19 pandemic between March and September 2020; these vaccination rates have continued to lag behind.
New Data Show Combination Antibody Treatment Reduces Risk of Death in Hospitalized COVID-19 Patients
The RECOVERY study demonstrated that an antibody combination therapy (REGEN-COV; Regeneron) improved survival in hospitalized patients, a first for COVID-19 antibody treatments.
FDA Approves Oral Blood Thinner For Children
The FDA approved Pradaxa (dabigatran etexilate) to treat venous thromboembolism in children aged 3 months to less than 12 years.
Read more on Contemporary Pediatrics
Half of Latinx, Black Medicare Beneficiaries Choose Medicare Advantage
Fifty-three percent of Latinx and 49% of Black Medicare beneficiaries choose enrollment in Medicare Advantage; seeing average annual savings of $1,113 and $1,270, respectively, compared to Traditional Medicare.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
